180710 – TG Tasly agreement PR
Category: TG6002
First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma
20171026-PR-TG6002
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
Laetitia Fend, et al. Cancer Research, July 2017, DOI: 10.1158/0008-5472.CAN-16-2165 – Download the article Publication
Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies
Johann Foloppe, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation
